As part of a 15% YTD increase in R&D spending to $4.8B, AbbVie made a $650 million upfront payment for a licensing agreement with RemeGen. This major investment in external innovation signals a need for advanced clinical trial management, data analytics, and collaboration platforms to manage its expanding pipeline.
Filing excerpt
Acquired IPR&D and milestones expense for the six months ended June 30, 2026 included an upfront charge of $650 million related to a license agreement with RemeGen Co., Ltd.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10qjointVentureGet every 10-Q signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/120898bc-d8d6-485e-9030-e17080e126c7 returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "120898bc-d8d6-485e-9030-e17080e126c7",
"signal_type": "sec-10q",
"signal_subtype": "jointVenture",
"detected_at": "2026-08-04T07:07:38.097+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "As part of a 15% YTD increase in R&D spending to $4.8B, AbbVie made a $650 million upfront payment for a licensing agreement with RemeGen. This major investment in external innovation signals a need for advanced clinical trial management, data analytics, and collaboration platforms to manage its expanding pipeline.",
"metrics": {
"pct": 0.15,
"timeframe": "current_year",
"pct_context": "YTD increase in R&D expenses",
"dollar_context": "Upfront charge for license agreement with RemeGen Co., Ltd.",
"dollar_millions": 650
},
"summary": "AbbVie pays $650M upfront in R&D licensing deal with RemeGen, boosting R&D spend 15%",
"excerpts": "Acquired IPR&D and milestones expense for the six months ended June 30, 2026 included an upfront charge of $650 million related to a license agreement with RemeGen Co., Ltd.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm",
"filing_date": "2026-08-03",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "New entity needs",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/120898bc-d8d6-485e-9030-e17080e126c7 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.